Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.

导出 OA

翻译打印收藏纠错

作者： Jennifer J,Mueller ^[1] ; Qin C,Zhou ^[2] ; Alexia,Iasonos ^[2] ; Roisin E,O'Cearbhaill ^[3] ; Farah A,Alvi ^[1] ; Amr,El Haraki ^[1] ; Ane Gerda Zahl,Eriksson ^[1] ; Ginger J,Gardner ^[4] ; Yukio,Sonoda ^[4] ; Douglas A,Levine ^[4] ; Carol,Aghajanian ^[3] ; Dennis S,Chi ^[4] ; Nadeem R,Abu-Rustum ^[4] ; Oliver,Zivanovic ^[5]

作者单位： Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States. ^[1] Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States. ^[2] Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States; Department of Medicine, Weill Cornell Medical College, New York, NY, United States. ^[3] Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States; Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY, United States. ^[4] Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States; Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY, United States. Electronic address: zivanovo@mskcc.org. ^[5]

关键词 Advanced-stage ovarian cancer Interval debulking surgery Neoadjuvant chemotherapy Overall survival Primary debulking surgery Progression-free survival